Conference Coverage

Universal CAR-T therapy produces CRs in relapsed/refractory T-ALL


 

FROM AACR 2020

‘Very impressive’ early results

Dr. Wang said the responses observed in this trial are notable because T-ALL constitutes 20%-25% of all adult ALL and 12%-15% of all pediatric ALL. T-ALL is highly aggressive, with event-free and overall survival of less than 25% in the relapsed setting. Dr. Wang noted that, despite the high unmet medical need and lack of treatment options for T-ALL, the development of novel immunotherapies has lagged.

One challenge is that T-ALL and normal T cells share common surface antigens, so targeted therapies for T-ALL will also target normal T cells. Another challenge is the potential contamination by malignant cells in autologous T-cell products, Dr. Wang said, noting that this can be avoided with universal CAR T cells.

Further, CD7 is a good target for T-ALL because it is expressed in more than 95% of T-ALL patients, she added.

“[TruUCAR GC027] demonstrated a very promising early response rate ... and showed a manageable toxicity profile at all three dose levels,” Dr. Wang said in closing, noting that further evaluation is warranted.

Indeed, the results of this next-generation CAR T-cell trial are “very impressive,” said invited discussant Yvonne Y. Chen, PhD, of the University of California, Los Angeles.

There have been concerns that “off-the-shelf” CAR T-cell products like TruUCAR GC027 might be limited by factors such as a reduced level of CAR T-cell persistence and therefore reduced efficacy leading to a need for repeat dosing, Dr. Chen noted. However, Dr. Wang and her colleagues showed a 100% CR/CRi rate with a single dose of CAR T cells and without graft-versus-host disease or neurotoxicity, Dr. Chen emphasized.

“I think it’s also important to note, however, that there’s quite a high incidence rate of grade 3 or higher toxicities, including CRS,” Dr. Chen said. “I suspect this may have something to do with the fairly high dosing levels used in this trial.”

The “big question,” however, is durability of the response, Dr. Chen said. “And this is something that the field will really watch as this trial progresses beyond the 7-month monitoring period ... reported today.”

Dr. Wang is an employee of Gracell Biotechnologies. Dr. Chen is cofounder of Kalthera Therapeutics and a scientific adviser for Gritstone Oncology and Notch Therapeutics.

SOURCE: Wang X et al. AACR 2020, Abstract CT052.

Pages

Recommended Reading

Groups release guidelines for CAR T treatment in children
Journal of Clinical Outcomes Management
Hormonal contraceptive use linked to leukemia risk in offspring
Journal of Clinical Outcomes Management
Researchers propose new acute leukemia subtypes
Journal of Clinical Outcomes Management
Report details financial burden of blood cancers
Journal of Clinical Outcomes Management
Whole-genome sequencing demonstrates clinical relevance
Journal of Clinical Outcomes Management
Factors emerge for mitigating CD19 CAR T toxicity
Journal of Clinical Outcomes Management
Immunotherapies under investigation in newly diagnosed B-ALL
Journal of Clinical Outcomes Management
ASH preview: Key themes include tackling CAR T obstacles, sickle cell advances, VTE
Journal of Clinical Outcomes Management
CAR T cells produce complete responses in T-cell malignancies
Journal of Clinical Outcomes Management
COVID-19: Adjusting practice in acute leukemia care
Journal of Clinical Outcomes Management